- H.C. Wainwright BioConnect Conference, where an on-demand webcast will be available on January 10, 2022, starting at 7:00 a.m. EST.
- 40th Annual J.P. Morgan Healthcare Conference where a live audio webcast of the presentation will be available on January 13, 2022, at 10:30 a.m. EST.
About Freeline Therapeutics
Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated systemic gene therapies. The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases. Freeline uses its proprietary, rationally designed AAV vector, along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into the patient’s bloodstream. The Company’s integrated gene therapy platform includes in-house capabilities in research, clinical development, manufacturing, and commercialization. The Company has clinical programs in hemophilia B, Fabry disease, and Gaucher disease Type 1. Freeline is headquartered in the UK and has operations in Germany and the US.
David S. Arrington
Vice President Investor Relations & Corporate Communications
+1 (646) 668 6947